ROCKET PHARMACEUTICALS INC

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

RCKT$2.39-2.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Summary of Abbreviated Terms

Rocket Pharmaceuticals, Inc. may be referred to as Rocket, the Company, we, our or us, in this Quarterly Report, unless the context otherwise indicates. Throughout this Quarterly Report, we have used terms which are defined below:

AAV	Adeno-associated virus	ICD	Implantable cardiac defibrillator
ACM	Arrhythmogenic cardiomyopathy	IND	Investigational New Drug application
ASC	Accounting Standard Codification	IPR&D	In process research and development
ASGCT	American Society of Gene & Cell Therapy	KCCQ	Kansas City Cardiovascular Questionnaire
BAG3	BLC2-associated athanogene 3	LAD-I	Leukocyte Adhesion Deficiency-I
BAG3-DCM	BLC2-associated athanogene 3 mutations associated with dialted cardiomyopathy	LAMP2	Lysosome-associated membrane protein 2
BLA	Biologics License Application	LV	Lentiviral vector
BNP	Brain natriuretic peptide	MAA	Marketing Authorization Application
CHF	Congestive heart failure	NYHA	New York Heart Association
cGMP	Current Good Manufacturing Practice	Offering	Equity offering on December 12, 2024
CIRM	California Institute for Regenerative Medicine	PKD	Pyruvate Kinase Deficiency
CMC	Chemistry Manufacturing Controls	PKP2-ACM	Plakophilin-2 Arrhythmogenic Cardiomyopathy
CODM	Chief Operating Decision Maker	PSU	Performance Stock Unit
CRL	Complete Response Letter	PRIME	Priority Medicines
Cowen	Cowen and Company, LLC	Private Placement	Issuance of warrants on December 12, 2024
CTIS	Clinical Trials Information Systems	R&D	Research and development
DCM	Dilated cardiomyopathy	RBC	Red blood cell
DD	Danon Disease	Renovacor	Renovacor, Inc. acquired on December 1, 2022
DNA	Deoxyrubonucleic acid	RMAT	Regenerative Medicine Advanced Therapy
EMA	European Medicines Agency	RSU	Restricted stock unit
ESB Lease Agreement	Office lease in the Empire State Building in NYC	RTW	RTW Investments, L.P
EU	European Union	SCD	Sudden cardiac death
FA	Fanconi Anemia	SEC	Securities and Exchange Commission
FANCA	Fanconi Anemia Complementation Group A	Stanford	Center for Definitive and Curative Medicine at Stanford University School of Medicine
FDA	U.S. Food and Drug Administration	UCLA	University of California, Los Angeles
GMP	Good Manufacturing Practice	U.S.	United States
HNJ	Hospital Infantil de Niño Jesús	U.S. GAAP	U.S. Generally Accepted Accounting Principles
HSCT	Hematopoietic stem cell transplant

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.